De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
I'rom Group Inkomsten in het verleden
Verleden criteriumcontroles 1/6
I'rom Group has been growing earnings at an average annual rate of 11.7%, while the Healthcare industry saw earnings growing at 6.9% annually. Revenues have been growing at an average rate of 13.1% per year. I'rom Group's return on equity is 6.2%, and it has net margins of 4.6%.
Belangrijke informatie
11.7%
Groei van de winst
11.2%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 7.9% |
| Inkomstengroei | 13.1% |
| Rendement op eigen vermogen | 6.2% |
| Nettomarge | 4.6% |
| Volgende winstupdate | 05 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe I'rom Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 17,697 | 815 | 6,039 | 606 |
| 31 Mar 24 | 17,740 | 1,415 | 5,688 | 682 |
| 31 Dec 23 | 17,323 | 1,276 | 5,558 | 885 |
| 30 Sep 23 | 17,390 | 1,651 | 5,246 | 730 |
| 30 Jun 23 | 18,218 | 2,366 | 4,915 | 940 |
| 31 Mar 23 | 18,351 | 2,542 | 4,708 | 859 |
| 31 Dec 22 | 17,913 | 2,421 | 4,150 | 1,077 |
| 30 Sep 22 | 18,493 | 3,221 | 4,594 | 635 |
| 30 Jun 22 | 17,097 | 2,770 | 4,151 | 682 |
| 31 Mar 22 | 15,693 | 1,961 | 4,126 | 582 |
| 31 Dec 21 | 15,100 | 2,115 | 4,266 | 0 |
| 30 Sep 21 | 14,667 | 1,777 | 3,591 | 318 |
| 30 Jun 21 | 14,085 | 1,580 | 3,637 | 0 |
| 31 Mar 21 | 12,906 | 1,373 | 3,360 | 0 |
| 31 Dec 20 | 12,797 | 1,754 | 3,166 | 0 |
| 30 Sep 20 | 10,961 | 1,282 | 3,027 | 0 |
| 30 Jun 20 | 10,392 | 1,116 | 3,049 | 0 |
| 31 Mar 20 | 10,593 | 1,236 | 3,053 | 0 |
| 31 Dec 19 | 9,902 | 743 | 3,176 | -139 |
| 30 Sep 19 | 10,526 | 646 | 3,080 | 0 |
| 30 Jun 19 | 10,700 | 918 | 2,970 | 0 |
| 31 Mar 19 | 10,578 | 912 | 2,834 | 0 |
| 31 Dec 18 | 10,384 | 788 | 2,750 | 50 |
| 30 Sep 18 | 9,459 | 857 | 2,715 | -59 |
| 30 Jun 18 | 9,222 | 489 | 2,629 | 0 |
| 31 Mar 18 | 8,621 | 1,558 | 2,439 | 0 |
| 31 Dec 17 | 8,109 | 1,873 | 2,257 | -10 |
| 30 Sep 17 | 6,949 | 1,660 | 1,985 | -2 |
| 30 Jun 17 | 5,640 | 1,606 | 1,708 | 0 |
| 31 Mar 17 | 4,890 | 204 | 1,587 | 0 |
| 31 Dec 16 | 4,384 | -106 | 1,377 | -14 |
| 30 Sep 16 | 4,246 | -326 | 1,517 | -11 |
| 30 Jun 16 | 4,148 | -825 | 1,893 | 0 |
| 31 Mar 16 | 4,114 | -868 | 1,965 | 0 |
| 31 Dec 15 | 4,164 | -960 | 2,150 | -14 |
| 30 Sep 15 | 3,988 | -1,090 | 1,967 | -8 |
| 30 Jun 15 | 3,890 | -884 | 1,625 | 0 |
| 31 Mar 15 | 4,134 | -606 | 1,566 | 0 |
| 31 Dec 14 | 3,747 | -676 | 1,559 | 127 |
| 30 Sep 14 | 3,922 | -488 | 1,554 | 80 |
| 30 Jun 14 | 4,277 | -244 | 1,517 | 0 |
| 31 Mar 14 | 4,011 | -294 | 1,407 | 0 |
| 31 Dec 13 | 4,172 | -1 | 1,238 | 0 |
Kwaliteitswinsten: 2372 has a large one-off gain of ¥272.0M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: 2372's current net profit margins (4.6%) are lower than last year (13%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2372's earnings have grown by 11.7% per year over the past 5 years.
Versnelling van de groei: 2372's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 2372 had negative earnings growth (-65.6%) over the past year, making it difficult to compare to the Healthcare industry average (8.2%).
Rendement op eigen vermogen
Hoge ROE: 2372's Return on Equity (6.2%) is considered low.